Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2025 09:54 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to De
August 27, 2025 16:52 ET | Source: Countdown For A Cure

Countdown For A Cure Awards $350,000 Grant to Minovia Therapeutics to Advance Groundbreaking Mitochondrial Biomarker Research

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics...
August 27, 2025 07:15 ET | Source: Minovia Therapeutics

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure Foundation to Develop Mitochondria Blood-Based Biomarkers

HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial...
May 22, 2025 08:16 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
April 10, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
April 03, 2025 07:16 ET | Source: Minovia Therapeutics

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
September 26, 2024 12:34 ET | Source: Minovia Therapeutics

Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved...
January 29, 2024 12:05 ET | Source: Doheny Eye Institute

Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling

PASADENA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, is pleased to announce the publication of important new findings...
January 15, 2024 18:00 ET | Source: Global Market Insights Inc.

L-carnitine Market to reach $312.8 Mn by 2032, Says Global Market Insights Inc.

Selbyville, Delaware, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The L-carnitine market valuation is projected to cross USD 312.8 million by 2032, as reported in a research study by Global Market...
April 26, 2023 04:00 ET | Source: NRG Therapeutics Limited

NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair

STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...